The pharmaceutical corporation is closing its corporate venturing unit, and will instead invest in strategic partnerships with mid-sized companies.

The oncological drug developer backed by the firm of SR One's founder outstrips expectations as it raises $55m from its initial public offering, seeing its price rise after the first day of trading.

Pharmaceutical corporation Celgene has paid $350m upfront to acquire biopharma company Avila Therapeutics, with Novartis in line for an exit.

GlaxoSmithKline-backed ChemoCentryx is looking to raise up to $64m when it floats, hot on the heels of fellow biopharmaceutical company Verastem.

Chris Guiffre is the new senior vice president and chief business officer for nanopharmaceutical company Cerulean Pharma as it looks to build upon a $15m funding round.

The medical device company is planning to finance the launch of its drug delivery system with a $10m series C round with SonoSite among the backers.

The Fidelity-backed medical device company is preparing for a series B round that could raise up to $10m.

The Connecticut state government-funded investment fund takes the antibiotics researcher to an estimated more than $43m raised, with signatories on its previous filing from Novartis' corporate venturing unit.

Monsanto and GlaxoSmithKline are joining founder investor Atlas Venture in financing RaNA Therapeutics, which specialises in genetic research.